18 and older, any sex, with Hepatocellular Carcinoma or BCLC Stage B Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Grade 3 or Higher Treatment Related Adverse EventsPrimary· up to 18 months
Safety and tolerability will be assessed by the rate of grade 3 or higher Adverse Events (AEs), graded using the CTCAE version 5. The rate will be assessed using the Bayesian Predictive Probability approach. Due to early termination of the study, reported here is the number of participants that experienced any grade 3 or higher event.
Group
Value
95% CI
Atezolizumab and Bevacizumab in Combination With TACE
1
Response Rate in Solid TumorsSecondary· up to 18 months
Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) will be used to assess overall response rate. Complete Response (CR): disappearance of all target lesions, Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD). Due to early termination of the study, a formal overall response rate could not be calculated. Presented here is the overall response frequency by RECIST 1.1 criteria type.
Group
Value
95% CI
Atezolizumab and Bevacizumab in Combination With TACE
0
Atezolizumab and Bevacizumab in Combination With TACE
0
Atezolizumab and Bevacizumab in Combination With TACE
3
Atezolizumab and Bevacizumab in Combination With TACE
0
Response Rate in Hepatocellular CarcinomaSecondary· up to 18 months
Response Evaluation Criteria in Hepatocellular Carcinoma-Specific Modified RECIST (HCC mRECIST) will be used to assess overall response rate. Complete response (CR): When all visible tumor areas on the arterial phase disappear, indicating complete necrosis. Partial response (PR): A significant decrease (≥ 30%) in the size of the enhancing tumor areas on the arterial phase. Stable disease (SD): No significant change in tumor size, neither shrinkage nor progression. Progressive disease (PD): An increase in the size of the enhancing tumor areas on the arterial phase (≥ 20%) or the appearance of n
Group
Value
95% CI
Atezolizumab and Bevacizumab in Combination With TACE
0
Atezolizumab and Bevacizumab in Combination With TACE
0
Atezolizumab and Bevacizumab in Combination With TACE
3
Atezolizumab and Bevacizumab in Combination With TACE
0
Adverse events — posted to ClinicalTrials.gov
Time frame: 18 months.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Atezolizumab and Bevacizumab in Combination With TACE
There is an unmet need for patients with intermediate stage hepatocellular carcinoma (HCC). It is known that local tumor ablation can increase tumor immunogenicity by releasing tumor associated antigens, potentially increasing the response to immune therapy not just locally, but systemically. In addition, there is now positive data with immune therapy in advanced HCC, there is renewed interest in the combination of local therapy and systemic therapy in Barcelona Clinic Liver Clinic B (BCLC B) patients with systemic therapies other than sorafenib. Based on this data, the investigators plan to examine the atezolizumab and bevacizumab combination with Transarterial Chemoembolization (TACE) in patients with BCLC B HCC.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
NCT05665348 — Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With He
· Phase 2, PHASE3
· completed
NCT05180006 — Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy
· Phase 2
· terminated
NCT05007613 — Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
· Phase 2
· completed
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
· Phase 2
· recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors
· Phase 3
· recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
· Phase 2
· recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer
· Phase 1
· recruiting
Other Yale University trials
Trials by the same sponsor.
NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking
· Phase 2
· not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing
· NA
· not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S
· NA
· not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa
· Phase 1, PHASE2
· not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 15 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05776875.